Bevacizumab Success Rate: — An Honest Look at the Numbers

They measure different things, and neither is more important in the abstract — it depends on what you are trying to understand. Response rate tells you whether the tumour shrank. Progression-free survival tells you how long treatment kept the cancer from growing. Overall survival tells you how long patients lived. Your oncologist focuses on whichever measure has the strongest evidence for your cancer type. For some cancers, response rate predicts longer survival well; for others, progression-free survival is the more meaningful number, and overall survival data may take years to mature.

Yes, substantially. Bevacizumab is approved and supported by evidence for specific cancers at specific stages. In some of those cancers, the evidence for adding it to chemotherapy is strong and consistent across multiple large trials. In others, the benefit is more modest and the decision involves weighing that against its side effects. Outside of established indications, the evidence is weaker or absent. This is why your oncologist will explain why bevacizumab makes sense for your particular cancer type rather than treating it as a general cancer treatment.

This is shorthand for what clinical trials showed in terms of median survival or median progression-free survival compared to treatment without bevacizumab. It means the group who received bevacizumab lived, or went without progression, for longer on average. It does not mean every person gains exactly that amount, and it does not mean the benefit is capped at that figure — some people gain considerably more. The phrase is an honest summary of population-level data from trials that NCCN and ASCO cite in their guidelines. It is not a forecast for you individually.

Typically through imaging done after a set number of cycles — CT scans or PET-CT scans, depending on your cancer type. In some cancers, blood markers are also part of the assessment. The scan looks at whether the tumour has shrunk, remained stable, or grown. Your oncologist will explain in advance what they are looking for and what the result means for continuing or changing treatment. If bevacizumab stops working, your team will discuss the next options rather than leaving you without a plan.

Bevacizumab is administered as day care at CION centres, which means you do not need an overnight admission for the infusion. Response assessment scans such as PET-CT are coordinated with partner imaging centres. Your treating oncologist at CION will explain the treatment schedule, how often you come in, and what monitoring is part of your plan. CION does not provide CAR-T or cell therapy; if those options become relevant to your case, you would be referred to a centre that offers them.

A second opinion is reasonable and a responsible oncologist will support it rather than discourage it. It is worth seeking if you are unsure why bevacizumab was recommended over another approach, or if something you read does not match what you were told. A second oncologist reviewing your case, your pathology, and your stage will either confirm the recommendation — which can be genuinely reassuring — or offer a different perspective. Both outcomes give you more information. Ask your team to share your records and scan images to make the process straightforward.